ENHERTU, AN ANTIbody drug conjugated with HER2, has been awarded the FDA's breakthrough therapy title to treat HER2-positive metastatic non-small cell lung cancer
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
AstraZeneca and Daiichi Sankyo's target HER2 antibody drug conjugated ENHERTU (FAM-trastustudeuxtecan-nxki) earned the U.SFood and Drug Administration's (FDA) breakthrough therapy designation (BTD) for treating HER2-positive metastatic non-small cell lung cancer (NSCLC)in December, Enhertu was approved by the FDA for the first time to treat patients who had previously received two or more metastatic HER2-positive breast cancers based on anti-HER2 therapyEnhertu has been awarded the FDA's BTD title for three types of cancer, which this week also earned the TITLE of HER2-positive metastatic gastric or gastroesophageal cobdiseasepreviously received the TITLE of HER2-positive breast cancer, prompting Enhertu to accelerate approval for her2-positive breast cancer in DecemberSix key trials of Enhertu are currently under way worldwide, involving a variety of HER2-positive cancers, such as breast, stomach and lung cancer, according to First Three PharmaceuticalsTrials of Enhertu's joint use with other anti-cancer therapies, including immunotherapy, are also under way
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
